Criteria Used to Determine Platinum Eligibility in Patients with Metastatic Urothelial Carcinoma: Results of a Physician Survey in Five European Countries
No Thumbnail Available
Authors
Gupta,Shilpa;Powles,Thomas;Kearney,Mairead;Panattoni,Laura;Land,Natalie;Flottemesch,Thomas;Sullivan,Patrick;Kirker,Melissa;Bharmal,Murtuza;Guenther,Silke;Costa,Nuno;Grande,Enrique
Check for full-text access
Issue Date
2025
Type
Article
Language
Keywords
Alternative Title
Abstract
BACKGROUND AND OBJECTIVE: Although, for decades, first-line treatment for metastatic urothelial carcinoma (mUC) has been based on eligibility for platinum-based chemotherapy (cisplatin or carboplatin), the platinum-ineligibility criteria used by European physicians in real-world practice are unclear. This study assessed the factors and clinical thresholds used by European physicians to determine platinum ineligibility and alignment with the published US thresholds. METHODS: Physicians in France, Germany, Italy, Spain, and the UK completed a quantitative online survey from August to September 2022. Physicians reported percentages of patients perceived as platinum eligible and factors considered when determining platinum ineligibility. A previous US-based survey was adapted to identify European consensus thresholds. Differences between European and US consensus thresholds were assessed using t tests. KEY FINDINGS AND LIMITATIONS: In total, 503 physicians (69% oncologists and 31% urologists) completed the survey. Respondents reported that 77% of treated patients with mUC were platinum eligible. European (vs US) consensus thresholds for platinum ineligibility were creatinine clearance of 80-yr-old person with metastatic urothelial cancer, whereas US doctors reported that they did not consider age in their decision.
Description
Citation
Publisher
License
Journal
European urology open science
Volume
81